Core Scientific and CoreWeave Acquisition - Rowley Law PLLC is investigating potential securities law violations by Core Scientific and its board of directors regarding the proposed acquisition by CoreWeave [1] - The acquisition involves stockholders receiving 0.1235 shares of CoreWeave common stock for each share of Core Scientific stock held [1] - The transaction is valued at approximately $9 billion and is expected to close in the fourth quarter of 2025 [1]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Organon & Co. regarding a class action lawsuit due to alleged misleading statements and concealment of material facts related to the company's capital allocation and dividend strategy [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that Organon & Co. provided overly positive statements to investors while concealing significant adverse facts about its priorities, particularly regarding capital allocation and a debt reduction strategy following the acquisition of Dermavant [3]. - The company's regular quarterly dividend was reduced by 70%, which was not disclosed to investors prior to the announcement [3]. Stock Price Impact - Following the announcement of the dividend cut, Organon's stock price plummeted from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [3]. Class Action Details - The class period for the lawsuit is defined as October 31, 2024, to April 30, 2025 [3]. - Shareholders are encouraged to register for the class action by July 22, 2025, to potentially be appointed as lead plaintiffs [4]. Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies engage in responsible business practices, seeking recovery for losses incurred due to misleading statements or omissions [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of West Pharmaceutical Services, Inc. regarding a class action lawsuit due to alleged misleading statements and operational inefficiencies that impacted the company's financial performance during the specified class period [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from February 16, 2023, to February 12, 2025 [3]. - Allegations include: - The company claimed strong visibility into customer demand while actually facing significant destocking in its high-margin HVP portfolio [3]. - The SmartDose device, marketed as a high-margin growth product, was found to be dilutive to profit margins due to operational inefficiencies [3]. - Margin pressures raised the risk of costly restructuring activities, including exiting continuous glucose monitoring contracts with long-term customers [3]. - Positive statements made by the defendants regarding the company's business and prospects were materially false or misleading [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by the deadline of July 7, 2025, to participate in the case without any cost or obligation [4]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [4]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices [5]. - The firm seeks recovery for investors who suffered losses due to false or misleading statements that led to artificial inflation of the company's stock [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Vestis Corporation regarding a class action lawsuit due to allegations of misleading statements and failure to meet growth expectations, leading to a significant drop in stock price [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that Vestis Corporation provided overly positive statements while concealing material adverse facts about its business growth capabilities, particularly its inability to execute strategic initiatives aimed at improving customer experience and retention [3]. Financial Performance - On May 7, 2025, Vestis announced disappointing financial results for Q2 of fiscal 2025, withdrew its revenue and growth guidance for the full fiscal year, and provided third-quarter guidance that was significantly below market expectations. The company cited "lost business in excess of new business" and "lower adds over stops" as reasons for its poor performance [3]. Stock Price Impact - Following the announcement of poor financial results, Vestis' stock price plummeted from $8.71 per share on May 6, 2025, to $5.44 per share on May 7, 2025, marking a decline of approximately 37.54% in just one day [3]. Class Action Details - Shareholders who purchased shares of Vestis during the class period from May 2, 2024, to May 6, 2025, are encouraged to register for the class action lawsuit, with a deadline for lead plaintiff appointment set for August 8, 2025 [4]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and seeks recovery for those who suffered losses due to misleading statements or omissions by companies, emphasizing the importance of responsible business practices [5].

Core Viewpoint - Fortrea Holdings Inc. is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its financial projections and business model [3][4]. Group 1: Allegations - The complaint claims that Fortrea overestimated the revenue contributions from its long-term projects, known as the Pre-Spin Projects, for the year 2025 [3]. - It is alleged that Fortrea overstated the cost savings expected from exiting transition services agreements [3]. - The company's previously announced EBITDA targets for 2025 were inflated as a result of these misstatements [3]. - The viability of Fortrea's post-spin-off business model and its financial prospects were also overstated [3]. - Overall, the company's public statements were materially false and misleading throughout the relevant period [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as July 3, 2023, to February 28, 2025 [3]. - Shareholders are encouraged to register for the class action by the deadline of August 1, 2025, to potentially become lead plaintiffs [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - Rowley Law PLLC is investigating potential securities law violations related to the proposed acquisition of Guaranty Bancshares, Inc. by Glacier Bancorp, Inc. [1] Group 1: Acquisition Details - The proposed acquisition involves stockholders of Guaranty Bancshares receiving 1.00 share of Glacier Bancorp common stock for each share of Guaranty Bancshares stock held [1] - The transaction is valued at approximately $476.2 million and is expected to close in the fourth quarter of 2025 [1]

Core Viewpoint - The Schall Law Firm is investigating PTC Therapeutics, Inc. for potential violations of securities laws related to misleading statements and failure to disclose important information to investors [1][2]. Group 1: Investigation Details - The investigation centers on whether PTC issued false or misleading statements regarding the results of the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Huntington's disease patients [2]. - PTC announced that the study met its primary endpoint of reducing blood Huntingtin (HTT) protein levels with a significant p-value of less than 0.0001 at Week 12, along with favorable safety and tolerability [2]. - Analysts suggest that a Phase 3 study is necessary to confirm if the treatment effectively slows the progression of Huntington's disease, leading to a significant drop in PTC's share price by over 18.6% on the announcement day [2].

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ: PEPG). Shareholders who purchased shares of PEPG during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/pepgen-inc-loss-submission-form/?id=153444&from=3 CLASS PERIOD: March 7, 2024 to March ...

NEW YORK, June 12, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Red Cat Holdings, Inc. (NASDAQ: RCAT).Shareholders who purchased shares of RCAT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/red-cat-holdings-inc-loss-submission-form/?id=152578&from=4CLASS PERIOD: March 18, ...

Core Viewpoint - The Schall Law Firm is investigating claims against NWTN Inc. for potential violations of securities laws, particularly regarding misleading statements and failure to disclose critical information to investors [1][2]. Group 1: Investigation Details - The investigation centers on whether NWTN issued false or misleading statements and failed to disclose important information relevant to investors [2]. - On May 28, 2025, NWTN announced it received a determination notice from Nasdaq indicating that its securities would be delisted due to non-compliance with listing rules [2]. Group 2: Legal Representation - The Schall Law Firm offers free consultations for shareholders who may have suffered losses and encourages them to discuss their rights [3]. - The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [3].